KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. (KALV): 7 pipeline candidates · 1 upcoming catalyst · ~60 mo cash runway · 10 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
60.2 months
D/E -17.74 · 7% dilution
Lead: Approved
7 candidates
1 upcoming, next in ~4605d
0 buys · 32 sells (180d)
A transparent, data-derived signal for KalVista Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.4B
Cash
$213.8M
Quarterly Burn
$14.5M
Runway
60.2 mo
Revenue
$40.9M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| drug | Phase 3 |
| ekterly | Approved |
| factor xiia inhibitor | Preclinical |
| factor xiia inhibitor program | Preclinical |
| kvd824 | Phase 2 |
| kvd900 | Phase 3 |
| sebetralstat odt | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
181
Total value held
$1.19B
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 4,768,712 | $96.0M |
| tang capital management llc | 4,573,530 | $92.1M |
| blackrock, inc. | 3,795,897 | $76.4M |
| vanguard capital management llc | 3,660,934 | $73.7M |
| woodline partners lp | 3,019,840 | $60.8M |
| silverarc capital management, llc | 2,876,407 | $57.9M |
| caption management, llc | 2,430,000 | $48.9M |
| state street corp | 1,955,844 | $39.4M |
| millennium management llc | 1,912,146 | $38.5M |
| vestal point capital, lp | 1,850,000 | $37.2M |
Showing top 10 of 181 institutional holders of KalVista Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in KalVista Pharmaceuticals, Inc.'s pipeline?
KalVista Pharmaceuticals, Inc. (KALV) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is KalVista Pharmaceuticals, Inc.'s lead drug candidate?
KalVista Pharmaceuticals, Inc.'s most advanced tracked candidate is drug (Phase 3) for Hereditary Angioedema.
What is KalVista Pharmaceuticals, Inc.'s next catalyst?
KalVista Pharmaceuticals, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: EKTERLY" — expected January 26, 2039.
What is KalVista Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, KalVista Pharmaceuticals, Inc. has approximately 60.2 months of cash runway.
What is KalVista Pharmaceuticals, Inc.'s market capitalization?
KalVista Pharmaceuticals, Inc.'s market capitalization is approximately $1.4B.
Get the full picture on KalVista Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.